Jul. 7 at 11:35 AM
Citizens reiterated
$LRMR Market Outperform-
$18
$LXEO $SLDB $BIIB $DSGN PTCT
Citizens said - This Thursday (July 9) at 10 a.m. ET, we will host FARA CEO Jennifer Farmer to discuss recent developments in the Friedreich's Ataxia (FA) pipeline on the heels of updated data from Larimar Therapeutic's ongoing open-label trial of nomlabofusp; we reiterate our Market Outperform rating and
$18 risk-adjusted, DCF-derived price target.
Ms. Farmer will be able to provide additional context on nomlabofusp's perceived benefit/risk profile from the patient community perspective.
Additionally, we plan to discuss real world feedback on Skyclarys' [BIIB] adoption, as well as enthusiasm for other pipeline programs, including Lexeo's (LXEO, NC) LX2006, Design Therapeutics's (DSGN, NC) DT-216P2, and Solid's (SLDB, MO,
$15 PT, Turkcan) SGT-212.
